Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MRK
stocks logo

MRK

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
15.86B
-1.56%
2.055
-9.88%
17.14B
+2.9%
2.455
+56.39%
16.39B
+4.88%
2.187
+27.13%
Estimates Revision
The market is revising Downward the revenue expectations for Merck & Co., Inc. (MRK) for FY2025, with the revenue forecasts being adjusted by -0.31% over the past three months. During the same period, the stock price has changed by -14.28%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.31%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.16%
In Past 3 Month
Stock Price
Go Down
down Image
-14.28%
In Past 3 Month
17 Analyst Rating
up Image0
Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is 102.88 USD with a low forecast of 82.00 USD and a high forecast of 138.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
7 Hold
0 Sell
Moderate Buy
up Image0
Current: 78.240
sliders
Low
82.00
Averages
102.88
High
138.00
up Image0
Current: 78.240
sliders
Low
82.00
Averages
102.88
High
138.00
Citigroup
Andrew Baum
Strong Buy
to
Hold
Downgrades
$115 → $84
2025-05-14
Reason
Citigroup
Andrew Baum
Price Target
$115 → $84
2025-05-14
Downgrades
Strong Buy
to
Hold
Reason
Cantor Fitzgerald
Carter Gould
Hold
Initiates
$85
2025-04-22
Reason
Cantor Fitzgerald
Carter Gould
Price Target
$85
2025-04-22
Initiates
Hold
Reason
Guggenheim
Vamil Divan
Strong Buy
Reiterates
$115
2025-04-17
Reason
Guggenheim
Vamil Divan
Price Target
$115
2025-04-17
Reiterates
Strong Buy
Reason
Deutsche Bank
James Shin
Strong Buy
to
Hold
Downgrades
$128 → $105
2025-02-18
Reason
Deutsche Bank
James Shin
Price Target
$128 → $105
2025-02-18
Downgrades
Strong Buy
to
Hold
Reason
Guggenheim
Vamil Divan
Strong Buy
Maintains
$122 → $115
2025-02-12
Reason
Guggenheim
Vamil Divan
Price Target
$122 → $115
2025-02-12
Maintains
Strong Buy
Reason
Guggenheim analyst Vamil Divan lowered the firm's price target on Merck to $115 from $122 and keeps a Buy rating on the shares. The firm is updating its company model following Q4 earnings and the company's initial FY25 guidance, noting that its lower target is mainly driven by lower sales estimates for Gardasil, partially offset by higher expectations on management's ability to execute on converting patients to subcutaneous Keytruda.
Morgan Stanley
Terence Flynn
Hold
Maintains
$113 → $106
2025-02-05
Reason
Morgan Stanley
Terence Flynn
Price Target
$113 → $106
2025-02-05
Maintains
Hold
Reason
Morgan Stanley analyst Terence Flynn lowered the firm's price target on Merck to $106 from $113 and keeps an Equal Weight rating on the shares. The company's 2025 guidance came in below expectations as Gardasil demand in China remains weak and the firm is reducing its estimates, thought more broadly, the focus remains on the Keytruda tail / loss of exclusivity and the progress with Merck's pipeline efforts, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Merck & Co Inc (MRK.N) is 8.45, compared to its 5-year average forward P/E of 17.30. For a more detailed relative valuation and DCF analysis to assess Merck & Co Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
17.30
Current PE
8.45
Overvalued PE
31.90
Undervalued PE
2.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
11.92
Current EV/EBITDA
7.00
Overvalued EV/EBITDA
16.75
Undervalued EV/EBITDA
7.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PS
4.16
Current PS
2.91
Overvalued PS
4.67
Undervalued PS
3.66

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

MRK News & Events

Events Timeline

(ET)
2025-05-21
14:27:04
RFK Jr.'s MAHA Report expected to criticize food additives, vaccines, WSJ says
select
link
2025-05-20 (ET)
2025-05-20
13:31:06
CMS demands on drug pricing 'extreme,' 'highly problematic,' says Leerink
select
2025-05-20
13:30:46
HHS says 'taking immediate steps to implement' Trump drug pricing order
select
link
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
05-22Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

  • Dividend-Yielding Stocks: Investors are increasingly turning to high dividend-yielding stocks during market uncertainty, with notable companies like Pfizer (7.47% yield), Merck (4.21% yield), and DENTSPLY SIRONA (4.04% yield) receiving various analyst ratings and updates on their recent developments.

  • Analyst Ratings and Market Updates: Analysts have provided mixed ratings for these stocks, with Pfizer securing a significant deal worth up to $6 billion, Merck initiating a Phase 3 trial for an esophageal cancer drug, and DENTSPLY SIRONA raising its sales guidance after better-than-expected financial results.

Preview
1.0
05-22Newsfilter
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference

  • Merck's Upcoming Event: Merck's CEO Robert M. Davis and Dr. Dean Y. Li will participate in a fireside chat at the Bernstein 41st Annual Strategic Decisions Conference on May 29, 2025, which will be available for live audio webcast.

  • Company Overview and Forward-Looking Statements: Merck aims to improve global health through innovative medicines and vaccines while acknowledging potential risks and uncertainties that could affect future performance as outlined in their forward-looking statements.

Preview
8.0
05-22SeekingAlpha
RFK Jr.'s MAHA report to target vaccine scheduling, food chemicals - report

  • Upcoming Report on Health Concerns: HHS Secretary Robert F. Kennedy Jr.'s report will address childhood vaccine schedules, additives in ultra-processed foods, and the influence of food and pharmaceutical lobbyists, while also calling for larger placebo-controlled trials for vaccines.

  • Focus on Children's Health: The report is expected to highlight issues such as pesticide impacts on children's health, criticism of federal nutrition guidelines regarding ultra-processed foods, and concerns about children's reduced outdoor activity due to smartphone use.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Merck & Co Inc (MRK) stock price today?

The current price of MRK is 78.24 USD — it has increased 1.64 % in the last trading day.

arrow icon

What is Merck & Co Inc (MRK)'s business?

Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. It sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company’s lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand.

arrow icon

What is the price predicton of MRK Stock?

Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is 102.88 USD with a low forecast of 82.00 USD and a high forecast of 138.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Merck & Co Inc (MRK)'s revenue for the last quarter?

Merck & Co Inc revenue for the last quarter amounts to 15.53B USD, decreased -1.56 % YoY.

arrow icon

What is Merck & Co Inc (MRK)'s earnings per share (EPS) for the last quarter?

Merck & Co Inc. EPS for the last quarter amounts to 2.01 USD, increased 7.49 % YoY.

arrow icon

What changes have occurred in the market's expectations for Merck & Co Inc (MRK)'s fundamentals?

The market is revising Downward the revenue expectations for Merck & Co., Inc. (MRK) for FY2025, with the revenue forecasts being adjusted by -0.31% over the past three months. During the same period, the stock price has changed by -14.28%.
arrow icon

How many employees does Merck & Co Inc (MRK). have?

Merck & Co Inc (MRK) has 72000 emplpoyees as of May 23 2025.

arrow icon

What is Merck & Co Inc (MRK) market cap?

Today MRK has the market capitalization of 193.30B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free